{"slug":"thymosin-alpha-1-postherpetic","verification":{"valid":true,"entries":1,"head":"1036ef289389558b4f6eca66bd9f77b052163ae370d90c1d6cd0729b2b656f96"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.03928,"waste_cost_usd":0,"total_tokens":28285,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.03928,"tokens_total":28285,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:58:58.481Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Thymosin Alpha 1 for Postherpetic Neuralgia: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nPostherpetic neuralgia (PHN) follows shingles, which is reactivation of latent varicella-zoster virus (VZV). After the rash clears, some people experience persistent burning, stabbing, or shooting pain along the affected nerve dermatome. This stems from nerve damage during the acute infection, ongoing low-level inflammation, and altered immune surveillance that fails to fully suppress the virus in dorsal root ganglia.\n\nDegeneration layers include direct neuronal injury from viral replication, central and peripheral sensitization creating chronic pain signals, and impaired cell-mediated immunity that normally keeps VZV latent. If your immune response to the virus is weakened by age, stress, or other factors, the virus can linger in a way that sustains nerve irritation rather than allowing full repair.\n\nThe condition persists when breakdown (nerve damage and inflammation) outruns repair (immune clearance and tissue recovery). Standard approaches often focus on symptom suppression with anticonvulsants, antidepressants, or opioids, which do not address the underlying immune control of the virus.\n\n## Why Thymosin Alpha-1 might help you\n\nThymosin Alpha-1 is discussed for its studied effects on immune modulation. If impaired cell-mediated immunity is part of your postherpetic picture, the peptide is examined because it supports T-cell function and cytokine balance rather than simply masking pain signals.\n\n1. Therefore for you: If viral latency control is a layer in your case, Thymosin Alpha-1 is discussed because studies examine its role in enhancing immune recognition of infected cells.\n2. If chronic inflammation contributes to ongoing nerve sensitivity, the compound is noted for observed shifts toward balanced immune responses in other infection contexts.\n3. Therefore for you: If tissue repair pathways matter after shingles-related damage, it targets restoration mechanisms instead of suppression alone.\n\n## How these fit together\n\nSingle-compound focus. Thymosin Alpha-1 maps to immune modulation. If your profile includes additional layers such as direct nerve repair or pain pathway modulation, other compounds would target those separately without overlap in this review.\n\n## What the evidence actually shows\n\nNo randomized controlled human trials specifically test Thymosin Alpha-1 in postherpetic neuralgia or shingles patients (tier: human - absent for this indication). Preclinical work includes one rodent study where thymosin alpha-1 reduced pain behaviors and spinal microglia-driven cytokines in a complete Freund's adjuvant model (tier: preclinical). General human data on Thymosin Alpha-1 come from trials in chronic hepatitis B, sepsis, and COVID-19, where it showed variable effects on immune markers and clinical outcomes across thousands of participants (tier: human). One 2025 multicenter sepsis trial found no reduction in 28-day mortality overall (tier: human). Reviews summarize use in over 11,000 subjects across 30+ trials for immune-related conditions, but none isolate PHN (tier: human - general). Anecdotal reports exist on forums but lack controls (tier: anecdotal).\n\n## What scientists say\n\nResearchers describe Thymosin Alpha-1 as an immune modulator that enhances T-cell maturation and response in viral and chronic disease settings. Publications note potential in infectious disease adjunctive use but emphasize the need for condition-specific trials. Reviews highlight inconsistent results in some acute settings and call for more targeted studies in post-viral syndromes (sources: PMC reviews and clinical trial reports).\n\n## What people say on Reddit\n\nUsers in long COVID, MCAS, and small fiber neuropathy communities report trying Thymosin Alpha-1 for immune-related fatigue or symptoms, with mixed self-described outcomes ranging from noticeable improvement to no change. Posts specifically linking it to shingles or PHN are rare; most discussion centers on general immune support or post-viral issues (tier: anecdotal).\n\n## What people say on X\n\nScattered posts mention Thymosin Alpha-1 alongside shingles recovery or vaccination discussions, often in context of immune support during or after outbreaks. Users reference it alongside other peptides for lingering symptoms, but reports remain individual and unverified (tier: anecdotal).\n\n## What we do not know\n\nDirect evidence for PHN is missing. It is unknown whether any immune changes observed in other diseases translate to reduced PHN pain or faster nerve recovery. Long-term effects, optimal timing after shingles, and interactions with standard PHN medications lack study. Human data specific to VZV reactivation or PHN do not exist in published trials.\n\n## Safety and limits\n\nClinical reviews of Thymosin Alpha-1 across large subject pools describe it as generally well-tolerated in studied populations. Individual responses vary, and self-experimentation carries unknown risks outside controlled settings. Regulatory status differs by region, with some restrictions noted in certain jurisdictions. This is not medical advice; consult qualified professionals for personal health decisions. Evidence remains limited for this specific use case.","claims":[{"id":"c1","text":"No randomized controlled human trials test Thymosin Alpha-1 specifically in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct evidence for the indication.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:58:58.100Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A rodent study showed thymosin alpha-1 reduced pain behaviors and spinal inflammation in an adjuvant pain model.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the only direct preclinical pain link mentioned.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:58:58.100Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Human trials of Thymosin Alpha-1 exist in hepatitis, sepsis, and COVID-19 involving thousands of participants with mixed results.","section":"What the evidence actually shows","tier":"human","source_ids":["s3","s4"],"source_status":"sourced","why_material":"Contextualizes available human data outside PHN.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:58:58.100Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss Thymosin Alpha-1 mainly for long COVID, MCAS, and neuropathy symptoms with self-reported variable outcomes.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Documents community reports without clinical validation.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:58:58.100Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"X posts occasionally reference Thymosin Alpha-1 in shingles or immune support contexts but remain individual accounts.","section":"What people say on X","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Captures public social media mentions.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:58:58.100Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10940365/","title":"Trigeminal Postherpetic Neuralgia review mentioning thymosin alpha-1 pain model","quote":"Thymosin alpha-1 inhibits complete Freund's adjuvant-induced pain...","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10940365/","title":"Preclinical pain study reference","quote":"Thymosin alpha-1 inhibits complete Freund's adjuvant-induced pain and production of microglia-mediated pro-inflammatory cytokines in spinal ...","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/","title":"Thymosin alpha 1 comprehensive review","quote":"Thymosin alpha 1 has been utilized in various cases to enhance cell-mediated immunity...","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://www.bmj.com/content/388/bmj-2024-082583","title":"Sepsis trial of thymosin α1","quote":"This trial found no clear evidence to suggest that thymosin α1 decreases 28 day all cause mortality...","link_status":"http_403","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/covidlonghaulers/comments/1r5ekd8/5_years_long_covid_thymosin_alpha_1_peptide_wow/","title":"Long COVID user experience post","quote":"I am now testing Thymosin Alpha 1 Peptide and I have to say WOW!","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"x","url":"https://x.com/sonii/status/2067417612758512078","title":"X post on peptides and shingles","quote":"Been natty my whole life brotha. Am taking Thymosin Alpha 1, BPC-157, KPV peptides tho to deal with tail end of shingles kek","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":25146,"tokens_out":3139,"cost":0.03928,"prev_hash":"genesis","hash":"1036ef289389558b4f6eca66bd9f77b052163ae370d90c1d6cd0729b2b656f96"}]}